Home › Trials › NCT06859268

Using retatrutide to help maintain weight loss in people with obesity

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity

PHASE3 · Eli Lilly and Company · NCT06859268

This study is testing if the medication retatrutide can help people with obesity keep off the weight they’ve lost.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment586 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company (industry)
Locations53 sites (Santa Ana, California and 52 other locations)
Trial IDNCT06859268 on ClinicalTrials.gov

What this trial studies

This study investigates the effectiveness of retatrutide in maintaining weight loss among individuals with obesity. Participants will undergo an 80-week lead-in phase where all will receive retatrutide dose 1, followed by a 36-week randomized, double-blinded phase where they will either continue with retatrutide or switch to a placebo. The total duration of participation in the study is approximately 125 weeks. The goal is to understand how well retatrutide helps sustain weight loss over time.

Who should consider this trial

Good fit: Ideal candidates are individuals with obesity who have previously attempted to lose weight through diet without success.

Not a fit: Patients who have undergone recent weight loss surgeries or have certain medical conditions, such as diabetes or a history of specific cancers, may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new option for individuals struggling to maintain weight loss after dieting.

How similar studies have performed: Other studies have shown promise with similar weight management approaches, but the specific use of retatrutide in this context is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria:

* Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
* Have a prior or planned surgical treatment for obesity
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity
* Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
* Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* Have had within the past 90 days before screening:

  * acute myocardial infarction
  * cerebrovascular accident (stroke)
  * hospitalization for unstable angina, or
  * hospitalization due to congestive heart failure
* Have New York Heart Association Functional Classification Class IV congestive heart failure
* Have a history of chronic or acute pancreatitis
* Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Where this trial is running

Santa Ana, California and 52 other locations

+3 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Obesity

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.